-
公开(公告)号:KR101865223B1
公开(公告)日:2018-06-08
申请号:KR1020110101291
申请日:2011-10-05
Applicant: 삼성전자주식회사
IPC: C07K16/28 , C07K16/30 , A61K39/395 , A61P35/00
CPC classification number: A61K39/39558 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C07K2317/53 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/92
Abstract: 항 c-Met 인간화항체및 이를포함하는암 예방또는치료용약학적조성물에관한것이다. 일구체예에따른항 c-Met 인간화항체및 이를포함하는암 예방또는치료용약학적조성물에의하면, 암을효율적으로예방또는치료할수 있다.
-
公开(公告)号:KR1020130036992A
公开(公告)日:2013-04-15
申请号:KR1020110101291
申请日:2011-10-05
Applicant: 삼성전자주식회사
IPC: C07K16/28 , C07K16/30 , A61K39/395 , A61P35/00
CPC classification number: A61K39/39558 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C07K2317/53 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/92
Abstract: PURPOSE: An anti-c-Met humanized antibody and use thereof are provided to efficiently prevent and treat cancer. CONSTITUTION: Anti-c-Met humanized antibody comprises a medium variable region consisting of amino acid sequence of sequence number 1 and a light variable region consisting of amino acid sequence of sequence number 2. The light variable region comprises a medium variable domain comprised of amino acid sequence of sequence number 3 and amino acid sequence of sequence number 4.
Abstract translation: 目的:提供抗c-Met人源化抗体及其用途,以有效预防和治疗癌症。 构成:抗c-Met人源化抗体包含由序列号1的氨基酸序列组成的中等可变区和由序列号2的氨基酸序列组成的轻度可变区。轻度可变区包含由氨基 序列号3的酸序列和序列号4的氨基酸序列。
-